Compare Novartis AG (NVS) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Prologis Inc — how do they compare? Novartis AG trades at $142.04 (market cap $274.00B), while Prologis Inc trades at $129.52 (market cap $120.98B). The key difference: Novartis AG is far larger — about 2.3× Prologis Inc's market cap, and Prologis Inc pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Prologis Inc for 102 Days on average.
| NVS | PLD | |
|---|---|---|
Market Cap | $274.00B | $120.98B |
Volume | 1,852,137 | 3,604,776 |
Sector | Health | Real Estate |
52-Week High | $168.62 | $149.96 |
52-Week Low | $121.80 | $111.23 |
Typical Hold Time | 82 Days | 102 Days |
Enterprise Value | $315.32B | $155.72B |
Dividend Yield | 3.31% | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Prologis (PLD) trades at $129.29, up 0.47% today, with a bearish technical signal from moving averages but bullish oscillators. The company has consistently beaten earnings expectations in recent quarters, with Q3 2026 results pending. Revenue grew to $8.79B in 2025, and net income margin stands strong at 45.79%. Recent news highlights strong leasing activity and data center growth potential, though the stock faces near-term resistance near $129.
The outlook for PLD is positive, supported by robust fundamentals and analyst consensus favoring a buy rating with a $155.15 price target. Key opportunities include e-commerce and data center demand driving rent growth. Risks involve rising debt levels, with debt-to-asset ratio increasing to 37.2% in 2025, and broader REIT sector volatility amid interest rate concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
